Methylphenidathydrochlorid 1 A Pharma

Methylphenidate Hydrochloride, the active ingredient in Methylphenidathydrochlorid 1 A Pharma, is a central nervous system stimulant presented as an oral tablet for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Methylphenidathydrochlorid 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourcing the product from EU‑regulated manufacturers.

Methylphenidate Hydrochloride is used within the central nervous system stimulant class to manage specific neurobehavioral conditions.

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in patients of various ages. - Narcolepsy: decreases daytime sleepiness and reduces the frequency of sudden sleep attacks.

Methylphenidate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach upset: nausea or abdominal discomfort.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychiatric symptoms: new or worsening psychosis, mania, or severe anxiety. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Growth suppression: notable decrease in height velocity in children.

When prescribing methylphenidate, clinicians should consider several precautionary measures to ensure safe use.

- Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Psychiatric history: screen for prior psychosis, bipolar disorder, or severe anxiety. - Substance abuse: avoid in patients with a history of drug dependence. - Growth monitoring: regularly assess height and weight in pediatric patients. - Concomitant MAO inhibitors: discontinue MAO inhibitors at least 14 days before starting methylphenidate. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Methylphenidate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use. - Tricyclic antidepressants: may increase cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: methylphenidate may reduce their effectiveness, requiring blood pressure monitoring. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase methylphenidate plasma levels. - Anticonvulsants (e.g., carbamazepine): may lower methylphenidate concentrations, reducing efficacy.